ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
DISCOVERY
From novel biology to clinical stage products.
Rich Pipeline
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Experienced team
Our team brings success from biotech pharma, and academia to OncoC4.
ONC-781, 782, 783, and 784
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
Exploring Our Pipeline:
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Rising To The Most Pressing Challenge In Immunotherapy
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
YANG LIU, PHD
CHIEF EXECUTIVE OFFICER & CHIEF SCIENTIFIC OFFICER
Latest News
OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors
ROCKVILLE, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a summary of preliminary clinical data from the ongoing Phase Ia clinical trial (PRESERVE-001, NCT04140526) evaluating the safety, tolerability and clinical activity of ONC-392 in cancer patients. ONC-392 is…
WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
SHANGHAI and ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline…
Merck to Acquire OncoImmune
KENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an…